Director, External Reporting and Accounting Policy

Healthcare

Mallinckrodt Pharmaceuticals, after merging with Endo in 2025, reorganized into two focused entities: Keenova Therapeutics, delivering branded specialty drugs, and Par Health, providing generics and sterile injectables. Together they offer a portfolio that spans specialty pharmaceuticals, active pharmaceutical ingredients, pain management, autoimmune and rare disease therapies, neonatal respiratory critical care, hemostasis products, and extracorporeal photopheresis. The dual structure allows each company to concentrate on its core expertise, enhancing innovation, operational efficiency, and patient outcomes. With a commitment to quality and a global distribution network, Mallinckrodt's integrated approach positions it as a leader in both branded and generics markets.